Abstract
Small cell lung carcinoma comprises approximately 10-20% of all lung cancers. At the time of diagnosis, 20-30% of patients have what is considered limited stage disease. Historically, chemotherapy has been the mainstay of treatment for small cell lung cancer, but more recent evidence from large meta-analyses have established the local control and overall survival advantages conferred by the addition of external beam thoracic radiotherapy in combination with chemotherapy for limited stage disease along with prophylactic cranial irradiation for complete responders. At present, radiotherapy is recommended to commence in concurrentoe with an earlier cycle of chemotherapy. Despite the established role of thoracic radiotherapy combined with chemotherapy for patients with limited stage disease, the optimal radiotherapy dose-fractionation schedule is still undefined. Recent investigational radiotherapy approaches applied to limited stage small cell lung cancer patients include hyperfractionated radiotherapy, dose-escalated daily radiotherapy, and hypofractionation. While several chemotherapy regimens and targeted systemic agents have been investigated in small numbers of small cell lung cancer patients, cisplatin with etoposide remains the current standard chemotherapy regimen for this cancer.
Keywords: Small cell lung cancer, combined modality therapy, chemoradiotherapy
Reviews on Recent Clinical Trials
Title: Combined Modality Treatment of Limited Stage Small Cell Carcinoma of the Lung
Volume: 3 Issue: 2
Author(s): Don Yee, Brita Danielson and Wilson Roa
Affiliation:
Keywords: Small cell lung cancer, combined modality therapy, chemoradiotherapy
Abstract: Small cell lung carcinoma comprises approximately 10-20% of all lung cancers. At the time of diagnosis, 20-30% of patients have what is considered limited stage disease. Historically, chemotherapy has been the mainstay of treatment for small cell lung cancer, but more recent evidence from large meta-analyses have established the local control and overall survival advantages conferred by the addition of external beam thoracic radiotherapy in combination with chemotherapy for limited stage disease along with prophylactic cranial irradiation for complete responders. At present, radiotherapy is recommended to commence in concurrentoe with an earlier cycle of chemotherapy. Despite the established role of thoracic radiotherapy combined with chemotherapy for patients with limited stage disease, the optimal radiotherapy dose-fractionation schedule is still undefined. Recent investigational radiotherapy approaches applied to limited stage small cell lung cancer patients include hyperfractionated radiotherapy, dose-escalated daily radiotherapy, and hypofractionation. While several chemotherapy regimens and targeted systemic agents have been investigated in small numbers of small cell lung cancer patients, cisplatin with etoposide remains the current standard chemotherapy regimen for this cancer.
Export Options
About this article
Cite this article as:
Yee Don, Danielson Brita and Roa Wilson, Combined Modality Treatment of Limited Stage Small Cell Carcinoma of the Lung, Reviews on Recent Clinical Trials 2008; 3 (2) . https://dx.doi.org/10.2174/157488708784223880
DOI https://dx.doi.org/10.2174/157488708784223880 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Developments in the Synthesis and Biological Activity of Aza-C-Nucleosides:Immucillins and Related Compounds
Current Medicinal Chemistry Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry Matrix Metalloproteinases: A Potential Therapeutic Target in Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Antioxidant Therapy for the Treatment of Oxidative Stress Associated to Cancer and Cancer- Related Anorexia/Cachexia
Current Nutrition & Food Science Clinicopathological Significance of Long Non-Coding RNA <i>GHET1</i> in Human Cancers: A Meta-Analysis
Current Pharmaceutical Biotechnology A Review of Recent Advancements in Anti-tubercular Molecular Hybrids
Current Medicinal Chemistry Immunotherapy of Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Expression Profiles and Bioinformatics Analysis of Full-length circRNA Isoforms in Gliomas
Current Bioinformatics Combination Therapy with Hepatocyte Growth Factor and Oseltamivir Confers Enhanced Protection Against Influenza Viral Pneumonia
Current Molecular Medicine Biological Evaluation of <sup>99m</sup>Tc-HYNIC-EDDA/tricine-(Ser)<sub>3</sub>-D4 Peptide for Tumor Targeting
Current Radiopharmaceuticals Non-covalent Interactions of Graphene with Polycyclic Aromatic Hydrocarbons
Current Organic Chemistry PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets Mechanism of Drug Sensitivity and Resistance in Melanoma
Current Cancer Drug Targets Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Does Cyclic Dependent Kinase 5 Play a Significant Role in Determination of Stroke Outcome? Possible Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Computer-Aided Detection (CADe) System for Detection of Malignant Lung Nodules in CT Slices - a Key for Early Lung Cancer Detection
Current Medical Imaging Novel Rational Drug Design Strategies with Potential to Revolutionize Malaria Chemotherapy
Current Medicinal Chemistry Small Molecules Targeting Ataxia Telangiectasia and Rad3-Related (ATR) Kinase: An Emerging way to Enhance Existing Cancer Therapy
Current Cancer Drug Targets